Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.

Subodh VermaC David MazerCatherine M ViscoliChristoph WannerAnne Pernille OfstadOdd Erik JohansenIsabella ZwienerJyothis T GeorgeJaved ButlerBernard Zinman

Published in: Diabetes, obesity & metabolism (2021)

Polyvascular disease with/without kidney dysfunction markedly increases the risk of HF/CV events. Empagliflozin consistently reduces risk, regardless of vascular bed and kidney function status.

Keyphrases

cardiovascular disease
type diabetes
oxidative stress
heart failure
adipose tissue
insulin resistance
skeletal muscle
weight loss
glycemic control